v3.25.1

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
CURRENT ASSETS
Cash and cash equivalents	$ 60,310	$ 67,234
Accounts receivable, net	17,740	19,688
Inventories	7,995	7,214
Other current assets	4,403	4,373
Total current assets	90,448	98,509
Property and equipment, net	161	42
Operating lease right-of-use assets	601	817
Intangible assets, net	2,213	2,276
Inventories, long-term	18,472	17,772
Other assets	718	488
TOTAL ASSETS	112,613	119,904
LIABILITIES
Accounts payable	4,627	6,662
Accrued liabilities	13,875	16,406
Operating lease liabilities, current portion	455	630
Total current liabilities	18,957	23,698
Accrued milestones	3,200	3,200
Operating lease liabilities, long-term portion	148	190
Other liabilities	851	812
TOTAL LIABILITIES	23,156	27,900
Commitments and contingencies (Note 9)
STOCKHOLDERS' EQUITY
Preferred stock, $0.0001 par value, 5,500,000 shares authorized and none issued at March 31, 2025 and December 31, 2024
Common stock, $0.0001 par value, 100,000,000 shares authorized at March 31, 2025 and December 31, 2024; 45,250,794 and 44,988,313 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	5	4
Additional paid-in capital	580,383	576,872
Accumulated other comprehensive income	1,401	2,264
Accumulated deficit	(492,332)	(487,136)
TOTAL STOCKHOLDERS' EQUITY	89,457	92,004
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 112,613	$ 119,904

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Y-mAbs Therapeutics, Inc. 10-Q